Daix - Inventiva (Euronext Paris and Nasdaq: IVA), a biopharmaceutical company specializing in the clinical development of small molecules administered orally for the treatment of non-alcoholic steatohepatitis (NASH), mucopolysaccharidoses (MPS)) and other diseases with significant unmet medical need, today announces its participation in the 'Piper Sandler 32 nd Annual Virtual Healthcare Conference'.
In this context, Inventiva will participate in investor meetings as well as in a discussion with an analyst from Piper Sandler.
About Inventiva
Inventiva is a biopharmaceutical company specializing in the clinical development of orally administered small molecules for the treatment of NASH, MPS and other diseases with significant unmet medical need.
Drawing on its expertise and significant experience in the development of compounds targeting nuclear receptors, transcription factors and epigenetic modulation, Inventiva is currently developing two drug candidates, as well as a large portfolio of several programs in the preclinical stage.
Lanifibranor, its most advanced drug candidate, is currently in development for the treatment of patients with NASH, a common and progressive chronic liver disease, for which there is currently no approved treatment. Inventiva recently published positive results from its Phase IIb clinical study evaluating lanifibranor for the treatment of patients with NASH and was granted Breakthrough Therapy and Fast Track status for lanifibranor in the treatment of NASH.
Odiparcil is the second clinical-stage drug candidate that Inventiva is developing for the treatment of patients suffering from a subtype of MPS, a group of rare genetic diseases. At the end of 2019, Inventiva published positive results from its Phase IIa clinical study evaluating odiparcil for the treatment of adult patients with MPS VI and obtained 'Fast Track' status in MPS VI for odiparcil in October 2020.
In parallel, Inventiva is in the process of selecting a drug candidate in oncology for its program in the Hippo signaling pathway. In addition, the Company has entered into a strategic partnership with AbbVie in the field of autoimmune diseases. AbbVie has initiated clinical development of ABBV-157, a drug candidate for the treatment of moderate to severe psoriasis, resulting from its collaboration with Inventiva. This partnership allows the payment to Inventiva of milestone payments based on the achievement of preclinical, clinical, regulatory and commercial objectives as well as royalties on the sales of products developed within the framework of this partnership.
The Company has a scientific team of around 70 people with strong expertise in biology, medicinal and computational chemistry, pharmacokinetics and pharmacology as well as in clinical development. In addition, Inventiva has a chemical library of approximately 240,000 molecules, of which approximately 60% are owned by the Company, as well as its own laboratories and equipment.
Inventiva is a company listed on compartment C of the regulated market of Euronext Paris (Euronext Paris: IVA - ISIN: FR0013233012) and on the Nasdaq Global Market in the United States (symbol: IVA).
Contact:
Frederic Cren
Tel: +33 3 80 44 75 00
Email: info@inventivapharma.com
INVENTIVA 
